Gilead’s COVID-19 treatment, remdesivir, is showing some promise in clinical trials which have seen swift recoveries of symptoms in severe COVID-19 patients, according to a STAT report.
According to the report, Gilead’s two Phase 3 trials involved 125 patients, 113 of whom were severe cases. The patients received daily doses of remdesivir.
“The best news is that most of our patients have already been discharged, which is great,” University of Chicago’s Kathleen Mullane said.
To read the full report on STAT, click here.